Multiple sclerosis is a disease of the central nervous system, not the liver or kidneys. The immune system attacks the protective coating around nerve fibers in the brain and spinal cord, and neither the liver nor the kidneys are direct targets. But “not a direct target” is not the same as “unaffected.” The medications used to treat MS, the bladder problems MS causes, the steroid infusions used during relapses, and even the autoimmune biology underlying the disease can all place stress on these organs in ways that matter for long-term health.
Why MS Medications Can Harm the Liver
The most common way MS touches the liver is through the drugs prescribed to slow the disease. Disease-modifying therapies work by dialing down or redirecting immune activity, and the liver, which processes nearly everything that enters the bloodstream, bears much of the metabolic load. A systematic review of case reports involving two widely used treatments, interferon beta-1a and glatiramer acetate, found that hepatic side effects were the second most frequently reported category, showing up in about one in seven cases reviewed.
The concern extends well beyond those two drugs. An observational study tracking over a thousand people with MS on oral therapies for up to two years found that newly elevated liver enzymes appeared in roughly 13% of those on dimethyl fumarate, about 12% on teriflunomide, and 30% on fingolimod. Among fingolimod users, nearly 3% developed liver toxicity significant enough to require clinical attention.
Those numbers might sound alarming, but context helps. An elevated liver enzyme on a blood test is not the same as liver damage. Most of the time, the increase is mild, temporary, and resolves either on its own or after a dose adjustment. Severe liver injury from MS drugs is rare. Still, a large analysis of the FDA’s adverse-event database found that certain MS therapies generated disproportionately high reporting rates for liver injury compared to other drugs in the system. Teriflunomide and fingolimod both showed reporting odds ratios above two for overall liver injury, meaning liver-related adverse events were reported at more than double the expected rate.
The practical takeaway is straightforward: if you are on an MS medication, your neurologist should be ordering periodic liver function tests. This is not optional vigilance. For teriflunomide in particular, liver enzyme monitoring is built into the prescribing guidelines because elevated alanine aminotransferase is one of the most common side effects seen in clinical trials.
Hepatitis B Reactivation on Newer Therapies
A less obvious liver risk comes from B-cell-depleting therapies like ocrelizumab, which has become one of the most prescribed MS drugs worldwide. Because these medications suppress a specific arm of the immune system, they can allow dormant infections to resurface. Hepatitis B virus reactivation has been documented in MS patients on ocrelizumab, including cases involving immune-escape viral mutations that made the reactivation harder to detect with standard screening tests.
This is why hepatitis B screening is recommended before starting B-cell-depleting treatment. If someone carries the virus, even if it has been dormant for years, the suppression of B cells can remove the immune surveillance that was keeping it in check. The liver takes the hit. A case report described reactivation with immune-escape mutations after ocrelizumab therapy, underscoring that even patients who test negative on some standard markers may still harbor the virus.
Kidney Risks from MS Treatments
Kidney problems from MS drugs are less common than liver problems but arguably more serious when they occur. Interferon beta-1a, one of the oldest MS treatments still in use, has been linked in rare cases to a condition called thrombotic microangiopathy, where tiny blood clots form in the kidney’s smallest vessels. One documented case involved a woman who developed hemolytic-uremic syndrome after five years on interferon beta-1a, requiring a kidney biopsy that confirmed the diagnosis. The likely mechanism involves interferon’s effect on blood vessel growth, which can disrupt the delicate vasculature inside the kidney.
Alemtuzumab, a potent treatment reserved for aggressive MS, carries its own kidney risks. Because it works by depleting and then allowing the immune system to rebuild, the new immune cells sometimes turn against the body’s own tissues. Both anti-GBM disease, a form of rapidly progressive kidney inflammation, and membranous nephropathy have been associated with alemtuzumab use. A Belgian consensus paper on managing these adverse renal events emphasized the need for monthly urine and blood monitoring for at least four years after each treatment course. One case report described a 24-year-old woman who developed anti-GBM disease just 10 months after receiving alemtuzumab, confirmed by high antibody levels and kidney biopsy.
Dimethyl fumarate, another common oral MS therapy, has been associated with proteinuria, the spillage of protein into the urine that signals kidney stress. In the same observational study mentioned earlier, about 3% of dimethyl fumarate users developed proteinuria within two years.
How Bladder Problems in MS Can Threaten the Kidneys
This is the pathway most people do not think about, yet it is probably the most common way MS indirectly harms the kidneys over time. MS frequently disrupts the nerve signals that control bladder function, creating what is known as a neurogenic bladder. Depending on which nerves are affected, the bladder may not empty completely, may contract unpredictably, or may lose the coordination between the muscle that squeezes and the sphincter that opens.
When the bladder does not empty well, urine can back up toward the kidneys. Over months and years, this creates conditions ripe for repeated urinary tract infections, kidney infections, and hydronephrosis, which is swelling of the kidney from urine that cannot drain properly. A narrative review of renal disease in MS highlighted that studies consistently show an increased risk of these complications in people with MS-related neurogenic bladder dysfunction.
The good news is that outright kidney deterioration from bladder problems in MS appears to be uncommon when people receive appropriate urological care. One study that applied strict criteria for renal deterioration found a rate of only 3% over intermediate-term follow-up in MS patients with neurogenic bladder. But the picture is not entirely reassuring. A separate study following patients with neurovesical dysfunction found that upper urinary tract abnormalities were present in about 12% of those who had repeat imaging, and that patients over 49 and those with abnormal bladder compliance were at higher risk.
The gap between 3% and 12% reflects differences in how “kidney damage” is defined and how closely patients are followed. The important point is that bladder management in MS is not just about comfort or convenience. Intermittent catheterization, medications that relax the bladder, and regular ultrasound monitoring of the upper urinary tract all serve to protect kidney function over the long haul.
What High-Dose Steroids Do to the Kidneys
When an MS relapse hits, the standard treatment is a short course of high-dose intravenous corticosteroids, typically methylprednisolone. These infusions reduce inflammation in the nervous system and speed recovery, but they also have immediate effects on the kidneys. Research has shown that high-dose glucocorticoids cause a rapid drop in serum phosphorus, driven by a direct effect on the kidney’s ability to reabsorb phosphate. Within hours of administration, the tubular handling of phosphate changes, and within days, there are measurable increases in the active form of vitamin D and increased urinary phosphate excretion.
For someone getting a single three-to-five-day course of steroids once or twice a year, these shifts are temporary and unlikely to cause lasting harm. But people with aggressive MS who require frequent steroid pulses face a different calculation. Repeated courses can contribute to bone thinning, altered calcium and phosphorus balance, and cumulative kidney stress. This is one reason neurologists try to limit relapse treatments to situations where the symptoms genuinely warrant it, rather than treating every minor flare.
When Autoimmune Disease Spills Beyond the Nervous System
MS is an autoimmune condition, and people with one autoimmune disease are statistically more likely to develop another. This creates a scenario where the liver or kidneys can be affected not by MS itself, and not by its treatment, but by a second autoimmune condition that shares the same underlying immunological tendency.
Primary biliary cholangitis is an autoimmune disease that attacks the small bile ducts inside the liver, gradually causing scarring and impaired liver function. Its coexistence with MS is rarely described but has been documented. A case report detailed a 35-year-old woman with a history of primary biliary cholangitis who then developed MS, presenting with unsteady gait and neurological symptoms. In another case, a patient being treated with ocrelizumab for MS developed liver failure that, after other causes were ruled out, turned out to be an overlap between primary biliary cirrhosis and autoimmune hepatitis.
These cases are uncommon enough that most MS patients will never encounter them. But they illustrate an important principle: when liver or kidney problems appear in someone with MS, the explanation is not always the medication. Sometimes the immune system is waging a separate campaign against a different organ, and teasing apart what is drug-related and what is disease-related requires careful diagnostic work.
The Bidirectional Relationship Between the Brain and Kidneys
Researchers have begun exploring a more fundamental question: does the central nervous system inflammation in MS actually provoke responses in the kidneys, and vice versa? A review article examining the cross-talk between kidneys and the central nervous system in MS argued that non-neural tissues play a more significant role in MS pathology than traditionally assumed. The authors pointed to metabolic and functional similarities between the brain and kidneys, suggesting that kidney tissue may respond to central inflammation in ways that affect the disease course.
This is still largely theoretical. The evidence consists of observations about shared receptors, overlapping metabolic pathways, and the fact that both organs are highly sensitive to oxidative stress and inflammation. No one has shown that MS directly damages kidney cells the way it damages myelin. But the idea that MS is a purely neurological disease with no systemic ripple effects is increasingly outdated. Research into metabolic changes supports this view. A study comparing people with newly diagnosed MS to healthy controls found that those with MS already had lower whole-body insulin sensitivity, and that autonomic nervous system imbalances in MS patients correlated with triglyceride levels in a pattern not seen in controls. The liver and kidneys are central players in lipid and glucose metabolism, so these findings, while preliminary, hint at systemic metabolic disruption early in the disease.
Which Organs Need Monitoring and When
The practical reality for someone living with MS is that liver and kidney surveillance depends heavily on which treatment you are taking. Here is how the monitoring landscape generally breaks down:
- Interferons: Liver function tests are standard before starting and periodically during treatment, given the established hepatic side-effect profile. Kidney function tests are less routine but warranted if any signs of hemolysis or hypertension appear.
- Teriflunomide: Requires liver enzyme checks before initiation, monthly for the first six months, and then periodically thereafter. This drug is contraindicated in people with severe liver impairment.
- Fingolimod: Liver function monitoring is recommended given the high rate of enzyme elevations seen in studies.
- Dimethyl fumarate: Routine blood work should include kidney function markers, given the association with proteinuria in a small but meaningful fraction of users.
- Alemtuzumab: Monthly urine and serum creatinine monitoring for at least four years after each treatment course, specifically to catch early signs of autoimmune kidney disease.
- Ocrelizumab and other B-cell therapies: Hepatitis B screening before starting, with liver monitoring during treatment.
Beyond medication monitoring, anyone with significant bladder dysfunction should have periodic renal ultrasounds. The frequency depends on the severity of the bladder problem and whether there is any history of urinary tract infections or incomplete emptying. This is the kind of monitoring that often falls through the cracks because urological care and neurological care happen in separate clinics, and neither specialist may think to ask about the other’s domain.
Why “Normal” Blood Work Does Not Mean Zero Risk
One misconception worth addressing: people with MS who have consistently normal liver and kidney tests sometimes assume they have nothing to worry about on that front. Standard blood panels are screening tools, not guarantees. Liver enzymes can be normal even when drug-induced changes are occurring at a cellular level, and serum creatinine, the most common kidney function marker, does not rise until a substantial amount of kidney function has already been lost. By the time creatinine is elevated, roughly half the kidney’s filtering capacity may be gone.
This does not mean everyone with MS should panic about their organs. It means that monitoring should be consistent, that new symptoms like dark urine, unexplained nausea, swelling in the legs, or changes in urination patterns deserve prompt attention, and that the conversation about organ health should be part of every MS treatment discussion rather than an afterthought. The liver and kidneys are not the battleground of MS, but they are bystanders close enough to the fight to get caught in the crossfire.
Pregnancy Planning and Organ Safety
For women with MS who are considering pregnancy, organ safety takes on extra layers. Several MS drugs are teratogenic or carry unknown fetal risks and must be stopped before conception, but the washout period varies. Teriflunomide, for instance, has an exceptionally long half-life and requires an accelerated elimination procedure to clear it from the body, partly because of its hepatic processing. Liver function needs to be confirmed as normal before and during this washout. Meanwhile, pregnancy itself places increased demands on the kidneys, which must filter a much larger blood volume. A woman whose kidneys are already subtly stressed from prior alemtuzumab-related autoimmune damage or from years of neurogenic bladder dysfunction faces compounded risk that should be evaluated by both a neurologist and a nephrologist before conception. The review literature on MS therapeutic safety monitoring emphasizes that pre-pregnancy planning must account for the organ-level effects of treatment history, not just the direct neurological picture.